Xenon Pharmaceuticals XENE Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $545.87M+368% | $199.16M+39.6% | $104.51M+19.3% | $135.38M-1.0% | $116.66M+98.1% | ||
| $548.88M+26.8% | $349.72M-27.8% | $357.75M-36.8% | $352.16M-39.8% | $432.97M-32.4% | ||
| $10.72M+47.7% | $10.39M+50.8% | $17.06M+264% | $11.61M+104% | $7.26M+7.2% | ||
| $1.11B+95.7% | $560.65M-11.7% | $480.14M-27.2% | $500.25M-31.3% | $565.54M-20.0% | ||
| $8.29M-14.5% | $8.72M-15.1% | $8.89M-12.5% | $9.21M-9.2% | $9.7M+3.2% | ||
| $6.29M-17.4% | $6.63M-16.5% | $6.96M-15.7% | $7.29M-15.0% | $7.62M-14.3% | ||
| $12.42M+14.1% | $12.86M+33.1% | $11.75M+1,015% | $11.05M+1,407% | $10.88M+2,620% | ||
| $1.39B+86.6% | $633.16M-20.7% | $607.84M-27.3% | $674.28M-23.7% | $743.28M-19.1% | ||
| $38.25M+24.8% | $40.26M+17.6% | $36.84M+30.1% | $31.59M+5.5% | $30.65M+46.6% | ||
| $1.56M+13.0% | $1.53M+11.9% | $1.5M+7.8% | $1.46M+7.8% | $1.38M+4.5% | ||
| $39.82M+24.3% | $41.79M+17.4% | $38.34M+29.1% | $33.05M+5.6% | $32.03M+44.1% | ||
| $5.93M-18.7% | $6.41M-16.1% | $6.83M-18.7% | $7.26M-16.4% | $7.29M-19.9% | ||
| $7.49M-13.6% | $7.94M-11.9% | $8.33M-14.9% | $8.72M-13.1% | $8.68M-16.8% | ||
| $3.25M— | $3.2M— | $3.16M— | —— | —— | ||
| $48.99M+24.6% | $51.4M+18.9% | $48.33M+26.9% | $40.3M+0.8% | $39.32M+25.5% | ||
| $2.42B+65.8% | $1.6B+9.7% | $1.48B+2.3% | $1.47B+2.0% | $1.46B+1.5% | ||
| $264.88M+27.1% | $228.23M+14.6% | $223.78M+18.8% | $213.89M+21.0% | $208.46M+27.4% | ||
| -$1.35B-39.7% | -$1.25B-38.5% | -$1.14B-36.7% | -$1.05B-36.1% | -$964.52M-35.3% | ||
| -$1.21M-44.9% | $335K+121% | $477K-64.3% | $113K+105% | -$836K+52.7% | ||
| $1.34B+90.0% | $581.76M-22.9% | $559.51M-29.9% | $633.98M-24.9% | $703.96M-20.7% | ||
| $1.39B+86.6% | $633.16M-20.7% | $607.84M-27.3% | $674.28M-23.7% | $743.28M-19.1% | ||
| $548.88M+26.8% | $349.72M-27.8% | $357.75M-36.8% | $352.16M-39.8% | $432.97M-32.4% | ||
| $1.17M— | $1.37M-6.7% | $812K— | $1.1M— | —— | ||
| $1.17M— | $1.37M-6.7% | $812K— | $1.1M— | —— | ||
| $6.29M-17.4% | $6.63M-16.5% | $6.96M-15.7% | $7.29M-15.0% | $7.62M-14.3% | ||
| $12.42M+14.1% | $12.86M+33.1% | $11.75M+1,015% | $11.05M+1,407% | $10.88M+2,620% | ||
| $6.29M-17.4% | $6.63M-16.5% | $6.96M-15.7% | $7.29M-15.0% | $7.62M-14.3% | ||
| $6.29M-17.4% | $6.63M-16.5% | $6.96M-15.7% | $7.29M-15.0% | $7.62M-14.3% | ||
| $38.25M+24.8% | $40.26M+17.6% | $36.84M+30.1% | $31.59M+5.5% | $30.65M+46.6% | ||
| $7.49M-13.6% | $7.94M-11.9% | $8.33M-14.9% | $8.72M-13.1% | $8.68M-16.8% | ||
| $264.88M+27.1% | $228.23M+14.6% | $223.78M+18.8% | $213.89M+21.0% | $208.46M+27.4% | ||
| $2.42B+65.8% | $1.6B+9.7% | $1.48B+2.3% | $1.47B+2.0% | $1.46B+1.5% | ||
| $8.31M+3.1% | $7.15M-4.6% | $7.11M-4.8% | $9.19M+23.9% | $8.05M+10.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Xenon Pharmaceuticals cover its short-term obligations?
- Its current ratio is 27.79 — current assets exceed current liabilities.
- Where does Xenon Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Xenon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.